The investigation centers on whether the proposed transaction provides fair value to the company's existing shareholders. Juan Monteverde, lead attorney at the New York-based firm, is inviting stockholders to review the details of the acquisition to determine if the terms warrant legal scrutiny. The firm, which operates out of the Empire State Building, emphasizes its track record in securities litigation as it begins this latest inquiry into the pharmaceutical sector.
Monteverde & Associates Launches Investigation into Supernus Sale
Supernus Pharmaceuticals shareholders face a pending acquisition by Indivior Pharmaceuticals that has drawn the attention of class action firm Monteverde & Associates. The legal team is currently probing the terms of the deal, which would see Supernus investors receive 1.5401 shares of Indivior common stock for each share currently held.
Investors holding common stock in Supernus Pharmaceuticals (NASDAQ: SUPN) may contact the firm directly to discuss potential concerns regarding the sale. Legal representatives are available via email at [email protected] or by phone at (212) 971-1341. Participation in the inquiry carries no cost or obligation for shareholders as the firm evaluates the fairness of the Indivior transaction.
Comments (0)
No comments yet. Be the first!